{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:03:56Z","timestamp":1790838236436,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ejmech.2019.06.058","type":"journal-article","created":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T01:50:56Z","timestamp":1561341056000},"page":"423-448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Evolution of HIV-1 reverse transcriptase and integrase dual inhibitors: Recent advances and developments"],"prefix":"10.1016","volume":"179","author":[{"given":"Muhammad Shoaib Ali","family":"Gill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharifah Syed","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5164-1970","authenticated-orcid":false,"given":"Nafees","family":"Ahemad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.06.058_bib1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ejmech.2018.09.013","article-title":"Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors","volume":"158","author":"Gu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib2","first-page":"52","article-title":"HIV sequence databases","volume":"5","author":"Kuiken","year":"2003","journal-title":"AIDS Rev."},{"key":"10.1016\/j.ejmech.2019.06.058_bib3","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/nrmicro3132","article-title":"Past, present and future: 30 years of HIV research","volume":"11","author":"Barr\u00e9-Sinoussi","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2019.06.058_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-011110-130254","article-title":"Pathogenic mechanisms of HIV disease","volume":"6","author":"Moir","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ejmech.2019.06.058_bib6","series-title":"HIV Life Cycle: Overview","first-page":"1","author":"Kirchhoff","year":"2013"},{"key":"10.1016\/j.ejmech.2019.06.058_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV","volume":"33","author":"De Clercq","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2019.06.058_bib8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2174\/156652308786848021","article-title":"Mechanisms governing lentivirus integration site selection","volume":"8","author":"Ciuffi","year":"2008","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ejmech.2019.06.058_bib9","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00044-016-1631-x","article-title":"Novel quinolone-3-carboxylic acid derivatives as anti-HIV-1 agents: design, synthesis, and biological activities","volume":"25","author":"Hajimahdi","year":"2016","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2019.06.058_bib10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.pbiomolbio.2004.07.001","article-title":"Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors","volume":"88","author":"Das","year":"2005","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.ejmech.2019.06.058_bib11","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1126\/science.282.5394.1669","article-title":"Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance","volume":"282","author":"Huang","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2019.06.058_bib12","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.3390\/v6093535","article-title":"Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors","volume":"6","author":"Singh","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2019.06.058_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.antiviral.2009.09.008","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989\u20132009)","volume":"85","author":"de B\u00e9thune","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2019.06.058_bib14","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jmb.2008.10.071","article-title":"Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition","volume":"385","author":"Sarafianos","year":"2009","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2019.06.058_bib15","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.cell.2005.04.024","article-title":"Crystal structures of RNase H bound to an RNA\/DNA hybrid: substrate specificity and metal-dependent catalysis","volume":"121","author":"Nowotny","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2019.06.058_bib16","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1093\/nar\/gkg881","article-title":"Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors","volume":"31","author":"Klumpp","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2019.06.058_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2009.11.004","article-title":"Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy","volume":"85","author":"McColl","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2019.06.058_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.drup.2010.05.001","article-title":"Resistance to HIV-1 integrase inhibitors: a structural perspective","volume":"13","author":"Mouscadet","year":"2010","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejmech.2019.06.058_bib19","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nrd1660","article-title":"Integrase inhibitors to treat HIV\/AIDS","volume":"4","author":"Pommier","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.06.058_bib20","doi-asserted-by":"crossref","first-page":"10932","DOI":"10.1038\/ncomms10932","article-title":"Production of unstable proteins through the formation of stable core complexes","volume":"7","author":"Levy","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2019.06.058_bib21","doi-asserted-by":"crossref","first-page":"8233","DOI":"10.1073\/pnas.150220297","article-title":"Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding","volume":"97","author":"Chen","year":"2000","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejmech.2019.06.058_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.aah5163","article-title":"Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome","volume":"355","author":"Passos","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2019.06.058_bib23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1107\/S2053230X18001553","article-title":"Cloning, purification and structure determination of the HIV integrase-binding domain of lens epithelium-derived growth factor","volume":"74","author":"Hannon","year":"2018","journal-title":"Struct. Biol. Cryst. Commun."},{"key":"10.1016\/j.ejmech.2019.06.058_bib24","doi-asserted-by":"crossref","first-page":"15910","DOI":"10.1073\/pnas.1002346107","article-title":"Structure-based modeling of the functional HIV-1 intasome and its inhibition","volume":"107","author":"Krishnan","year":"2010","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejmech.2019.06.058_bib25","article-title":"Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S\/GSK1349572)","volume":"111","author":"Hare","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.06.058_bib26","doi-asserted-by":"crossref","first-page":"20057","DOI":"10.1073\/pnas.1010246107","article-title":"Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance","volume":"107","author":"Hare","year":"2010","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejmech.2019.06.058_bib27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jmb.2006.08.097","article-title":"Crystal structures of clinically relevant Lys103Asn\/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097","volume":"365","author":"Das","year":"2007","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2019.06.058_bib28","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2217\/fvl.14.24","article-title":"Can the ever-promising target HIV reverse transcriptase-associated RNase H become a success story for drug development?","volume":"9","author":"Corona","year":"2014","journal-title":"Future Virol."},{"key":"10.1016\/j.ejmech.2019.06.058_bib29","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1021\/jm800245z","article-title":"Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection","volume":"51","author":"Summa","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib30","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2217\/fvl.12.56","article-title":"The molecular biology of HIV integrase","volume":"7","author":"Craigie","year":"2012","journal-title":"Future Virol."},{"key":"10.1016\/j.ejmech.2019.06.058_bib31","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jmb.2008.04.054","article-title":"Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors","volume":"380","author":"Chen","year":"2008","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2019.06.058_bib32","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ejmech.2012.02.015","article-title":"Hydroxyl may not be indispensable for raltegravir: design, synthesis and SAR studies of raltegravir derivatives as HIV-1 inhibitors","volume":"50","author":"Wang","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40242-014-3395-5","article-title":"Pharmacophore and docking-based 3D-QSAR studies on HIV-1 integrase inhibitors","volume":"30","author":"Zhang","year":"2014","journal-title":"Chem. Res. Chin. Univ."},{"key":"10.1016\/j.ejmech.2019.06.058_bib34","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1517\/13543776.2011.586631","article-title":"New first and second generation inhibitors of human immunodeficiency virus-1 integrase","volume":"21","author":"Pendri","year":"2011","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2019.06.058_bib35","first-page":"595","article-title":"Progress in HIV-1 integrase inhibitors: a review of their chemical structure diversity","volume":"15","author":"Hajimahdi","year":"2016","journal-title":"Iran. J. Pharm. Res. (IJPR)"},{"key":"10.1016\/j.ejmech.2019.06.058_bib36","doi-asserted-by":"crossref","first-page":"7253","DOI":"10.1021\/jm800893q","article-title":"From ligand to complexes. Part 2. Remarks on human immunodeficiency virus type 1 integrase inhibition by \u03b2-diketo acid metal complexes","volume":"51","author":"Bacchi","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib37","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.2174\/1381612043382648","article-title":"Closely related antiretroviral agents as inhibitors of two HIV-1 enzymes, ribonuclease H and integrase:\u201cKilling two birds with one stone\u201d","volume":"10","author":"Andr\u00e9ola","year":"2004","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2019.06.058_bib38","series-title":"Identification of Highly Conserved Residues Involved in the Inhibition of the HIV-1 Ribonuclease H Function by Diketoacid Derivatives, Antimicrobial Agents and Chemotherapy","author":"Corona","year":"2014"},{"key":"10.1016\/j.ejmech.2019.06.058_bib39","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.2174\/138161209788453266","article-title":"Designed multiple ligands: an emerging anti-HIV drug discovery paradigm","volume":"15","author":"Zhan","year":"2009","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2019.06.058_bib40","first-page":"815","article-title":"Multivalent agents: a novel concept and preliminary practice in Anti-HIV drug discovery","volume":"20","author":"Song","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib41","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed multiple ligands. An emerging drug discovery paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib42","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1021\/jm070512p","article-title":"Rationally designed dual inhibitors of HIV reverse transcriptase and integrase","volume":"50","author":"Wang","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib43","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.2174\/092986711796504619","article-title":"Diketo acids derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain","volume":"18","author":"Di Santo","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib44","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1128\/AAC.49.12.4884-4894.2005","article-title":"Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones","volume":"49","author":"Didierjean","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2019.06.058_bib45","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/AAC.00883-07","article-title":"Madurahydroxylactone derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and RNase H","volume":"52","author":"Marchand","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2019.06.058_bib46","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1126\/science.287.5453.646","article-title":"Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells","volume":"287","author":"Hazuda","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2019.06.058_bib47","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1021\/jm000176b","article-title":"4-Aryl-2, 4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells","volume":"43","author":"Wai","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib48","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2174\/092986712799320565","article-title":"Diketoacid inhibitors of HIV-1 integrase: from L-708,906 to raltegravir and beyond","volume":"19","author":"D Beare","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib49","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1021\/jm020037p","article-title":"Structure activity of 3-aryl-1, 3-diketo-containing compounds as HIV-1 integrase inhibitors","volume":"45","author":"Pais","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib50","doi-asserted-by":"crossref","first-page":"12623","DOI":"10.3390\/molecules200712623","article-title":"Integrase inhibitor prodrugs: approaches to enhancing the anti-HIV activity of \u03b2-diketo acids","volume":"20","author":"Nair","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2019.06.058_bib51","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.2174\/138161212802430440","article-title":"The development of HEPT-type HIV non-nucleoside reverse transcriptase inhibitors and its implications for DABO family","volume":"18","author":"Chen","year":"2012","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2019.06.058_bib52","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1021\/ci700271z","article-title":"Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB\/SA scoring","volume":"47","author":"Barreiro","year":"2007","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2019.06.058_bib53","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2174\/09298673113206660298","article-title":"Recent advances in the discovery and development of novel HIV-1 NNRTI platforms (Part II): 2009-2013 update","volume":"21","author":"Song","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.antiviral.2004.11.002","article-title":"6-[1-(4-Fluorophenyl) methyl-1H-pyrrol-2-yl)]-2, 4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in\u00a0vitro","volume":"65","author":"Tramontano","year":"2005","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2019.06.058_bib55","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1021\/jm0511583","article-title":"Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action","volume":"49","author":"Di Santo","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib56","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1021\/jm8001422","article-title":"Novel quinolinonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, and biological activities","volume":"51","author":"Di Santo","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib57","doi-asserted-by":"crossref","first-page":"8588","DOI":"10.1021\/jm401040b","article-title":"6-(1-Benzyl-1 H-pyrrol-2-yl)-2, 4-dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach","volume":"56","author":"Costi","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib58","doi-asserted-by":"crossref","first-page":"23873","DOI":"10.1039\/C8CP01843J","article-title":"Prediction of the binding mode and resistance profile for a dual-target pyrrolyl diketo acid scaffold against HIV-1 integrase and reverse-transcriptase-associated ribonuclease H","volume":"20","author":"Yang","year":"2018","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.ejmech.2019.06.058_bib59","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.antiviral.2016.09.008","article-title":"New insights into the interaction between pyrrolyl diketoacids and HIV-1 integrase active site and comparison with RNase H","volume":"134","author":"Corona","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2019.06.058_bib60","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1021\/jm501799k","article-title":"Structure\u2013activity relationship of pyrrolyl diketo acid derivatives as dual inhibitors of HIV-1 integrase and reverse transcriptase ribonuclease H domain","volume":"58","author":"Cuzzucoli Crucitti","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib61","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1021\/jm5001503","article-title":"Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase","volume":"57","author":"Costi","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib62","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1021\/acs.jmedchem.5b00159","article-title":"N-substituted quinolinonyl diketo acid derivatives as HIV integrase strand transfer inhibitors and their activity against RNase H function of reverse transcriptase","volume":"58","author":"Pescatori","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib63","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.bmcl.2008.01.025","article-title":"Synthesis of pyrimidine and quinolone conjugates as a scaffold for dual inhibitors of HIV reverse transcriptase and integrase","volume":"18","author":"Wang","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.058_bib64","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1016\/j.bmc.2010.05.004","article-title":"Pharmacophore and structure\u2013activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase","volume":"18","author":"Wang","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib65","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1016\/j.bmc.2008.02.007","article-title":"Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: introducing a diketoacid functionality into delavirdine","volume":"16","author":"Wang","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib66","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1016\/j.bmc.2016.09.025","article-title":"Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase","volume":"24","author":"Gu","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib67","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1021\/jm000255n","article-title":"Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations","volume":"44","author":"Rizzo","year":"2001","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib68","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1021\/ml1002162","article-title":"N-3 hydroxylation of pyrimidine-2, 4-diones yields dual inhibitors of HIV reverse transcriptase and integrase","volume":"2","author":"Tang","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2019.06.058_bib69","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1016\/j.bmcl.2011.02.069","article-title":"6-Benzoyl-3-hydroxypyrimidine-2, 4-diones as dual inhibitors of HIV reverse transcriptase and integrase","volume":"21","author":"Tang","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.058_bib70","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1021\/jm1014378","article-title":"3-Hydroxypyrimidine-2, 4-diones as an inhibitor scaffold of HIV integrase","volume":"54","author":"Tang","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib71","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1021\/acs.jmedchem.6b00040","article-title":"3-Hydroxypyrimidine-2, 4-dione-5-N-benzylcarboxamides potently inhibit HIV-1 integrase and RNase H","volume":"59","author":"Wu","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib72","doi-asserted-by":"crossref","first-page":"7717","DOI":"10.1021\/jm8007085","article-title":"Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1, 3 (2 H, 4 H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain","volume":"51","author":"Billamboz","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib73","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ejmech.2010.11.033","article-title":"2-Hydroxyisoquinoline-1, 3 (2H, 4H)-diones as inhibitors of HIV-1 integrase and reverse transcriptase RNase H domain: influence of the alkylation of position 4","volume":"46","author":"Billamboz","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib74","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.bmcl.2017.03.009","article-title":"Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors","volume":"27","author":"Xue","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.058_bib75","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1016\/j.bmc.2015.03.037","article-title":"Anti-HIV diarylpyrimidine\u2013quinolone hybrids and their mode of action","volume":"23","author":"Mao","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.058_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2018.06.036","article-title":"5-Hydroxypyrido [2, 3-b] pyrazin-6 (5H)-one derivatives as novel dual inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H and integrase","author":"Sun","year":"2018","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419305859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419305859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:00:28Z","timestamp":1759327228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419305859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":75,"alternative-id":["S0223523419305859"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.06.058","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of HIV-1 reverse transcriptase and integrase dual inhibitors: Recent advances and developments","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.06.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}